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Azithromycin (AZI), a broad-spectrum antibiotic, accumulates in polymorphonuclear cells and peripheral blood mononuclear
cells. The distribution of AZI in proinflammatory cells may be important to the anti-inflammatory properties. Previous studies
have described plasma AZI pharmacokinetics. The objective of this study was to describe the pharmacokinetics of AZI in whole
blood (concentration in whole blood [Cb]) and plasma (concentration in plasma [Cp]) of healthy subjects. In this study, 12 sub-
jects received AZI (500 mg once a day for 3 days). AZI Cb and Cp were quantified in serial samples collected up to 3 weeks after
the last dose and analyzed using noncompartmental and compartmental methods. After the last dose, Cb was greater than Cp.
Importantly, Cb, but not Cp, was quantifiable in all but one subject at 3 weeks. The blood area under the curve during a 24-h dos-
ing interval (AUC24) was 2-fold greater than the plasma AUC24, but simulations suggested that Cb was not at steady state by
day 3. Upon exploration of numerous models, an empirical 3-compartment model adequately described Cp and Cb, but Cp was
somewhat underestimated. Intercompartmental clearance (CL; likely representing cells) was lower than apparent oral CL (18
versus 118 liters/h). Plasma, peripheral, and cell compartmental volumes were 439 liters, 2,980 liters, and 3,084 liters, respec-
tively. Interindividual variability in CL was low (26.2%), while the volume of distribution variability was high (107%). This is the
first report to describe AZI Cb in healthy subjects, the distribution parameters between Cp and Cb, and AZI retention in blood for
up to 3 weeks following 3 daily doses. The model can be used to predict Cb from Cp for AZI under various dosing regimens. (This
study has been registered at ClinicalTrials.gov under registration no. NCT01026064.)
Azithromycin (AZI) is a 15-membered lactone-ring azalidestructurally related to the macrolide family of antibiotics. AZI
is approved for use worldwide as a broad-spectrum antibiotic to
treat a variety of community-acquired infections. It acts by bind-
ing to the 50S ribosomal subunit of susceptible organisms and
interfering with protein synthesis (1, 2). In addition, AZI and
other macrolides are investigational products with anti-inflam-
matory/immunomodulatory actions that may be beneficial for
those suffering from chronic pulmonary inflammatory syn-
dromes, such as cystic fibrosis (CF), bronchiolitis obliterans syn-
drome (BOS), chronic obstructive pulmonary disease (COPD),
asthma, and bronchiectasis (3–5).
The recommended dose of AZI for the treatment of acute re-
spiratory tract infections is 500 mg (10 mg/kg of body weight in
children) once daily for 3 days or 500 mg (10 mg/kg) on day 1,
followed by 250 mg (5 mg/kg) once daily for 4 days (6). The opti-
mal dose and dosing regimen of AZI for the treatment of chronic
lung inflammation, where chronic dosing is required for clinical
benefit, are unknown.
Various empirically selected dosing regimens were studied in
patients with chronic pulmonary inflammatory diseases. For ex-
ample, long-term, once-daily dosing was tested in CF patients at
dose levels of 250 or 500 mg (or the pediatric equivalent of 15
mg/kg, which corresponds to an adult dose of 750 mg) (7–13).
Once-daily dosing of 250 or 500 mg was also tested in patients
with COPD or asthma, respectively (14, 15). Dosing three times
weekly was evaluated in patients with BOS (250 mg thrice weekly
with or without a loading dose of 1,250 mg in the first week),
bronchiectasis (250 mg thrice weekly), CF (500 mg thrice weekly),
COPD (500 mg once daily over 3 days each week), and asthma (10
mg/kg once daily over 3 days each week) (16–26). Twice-weekly
dosing of 250 mg was assessed in patients with asthma or COPD
with or without a loading dose, and a dose of 500 mg twice weekly
was tested in patients with bronchiectasis (27–29). Finally, once-
weekly dosing was evaluated in patients with asthma (600 mg once
weekly with a loading dose of 1,800 mg or 1,000 mg once weekly) and
CF (1,000 to 1,250 mg or the pediatric equivalent) (10, 12, 30–33).
Other reported regimens included 500 mg daily for 6 days, followed
by 250 mg daily for 6 days, and weekly dosing of 250 mg daily for 3
days thereafter (in patients with bronchiectasis) and 500 mg daily
over 3 days every 3 weeks (in patients with COPD) (34, 35).
Despite such variety in dosing regimens and total weekly doses,
which ranged from 500 to 5,250 mg (adult equivalent of 15 mg/kg
daily for 7 days), beneficial effects of AZI were detected across the
trials and indications studied. Furthermore, a couple of studies
that compared different AZI regimens in CF patients did not show
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a major difference in efficacy or safety between a low (5 mg/kg)
and a high (15 mg/kg) daily dose of AZI or between 250 mg daily
and 1,200 mg weekly (9, 10). An improved understanding of the
systemic exposures in whole blood achieved after long-term treat-
ment with various dosing regimens of AZI, along with clarifica-
tion of its anti-inflammatory mode of action, would aid the inter-
pretation of the observed efficacy results and enable a rational
selection of doses and dosing schedules for clinical trials of AZI in
chronic inflammatory diseases.
In contrast to other macrolide agents, AZI distributes and ac-
cumulates extensively in a number of cells, including peripheral
blood mononuclear cells (PBMCs), polymorphonuclear leuko-
cytes (PMNs), and fibroblasts (36–39). The exceptionally high
accumulation of AZI in tissues is consistent with the ubiquitous
nature of the fibroblasts, which are cells found in virtually all tis-
sues (36, 40, 41). Consistent with the dibasic character of AZI, cell
fractionation studies showed that most of the cellular and tissue
AZI is stored in lysosomes (39, 42). While AZI accumulates exten-
sively in white blood cells, several studies showed little or no ac-
cumulation of AZI in erythrocytes (38, 43).
The pharmacokinetic profile of AZI is consistent with the rapid
and extensive uptake of this compound from the circulation into
intracellular compartments, followed by slow release. These dis-
tributional attributes of AZI lead to low serum concentrations,
widespread tissue distribution, a very long serum terminal half-
life of 78.6 h, and a large volume of distribution (V) (38, 41). AZI
binds to plasma proteins in a nonlinear fashion; the bound frac-
tion decreases from 51% at low concentrations in serum to 7% at
higher concentrations in serum (41).
Extensive accumulation of AZI in proinflammatory cells, in
combination with bactericidal activity, has been proposed to con-
tribute to the eradication of the phagocytized organisms and to be
relevant to the therapeutic efficacy of AZI against certain infec-
tions (43, 44). In addition, AZI reduces inflammatory cell migra-
tion by direct effects on neutrophils (45) and modifies monocyte
activation and differentiation (46, 47). Therefore, AZI accumula-
tion in proinflammatory cells may be important to the anti-in-
flammatory properties of AZI.
Studies published to date have characterized the pharmacoki-
netic parameters of AZI in plasma and its accumulation in various
types of isolated white blood cells in either healthy or CF patients
(48–51). However, no pharmacokinetic investigation has been
carried out to simultaneously address the distribution of AZI be-
tween plasma and whole blood in healthy subjects. The aim of this
study was to develop a population pharmacokinetic model to
characterize the concentration-time profile of AZI in plasma and
whole blood following three 500-mg doses in healthy male volun-
teers and to simulate the pharmacokinetic profiles of AZI upon
long-term administration.
MATERIALS AND METHODS
Study design and subjects. Data were obtained from a study designed to
address the utility of the cantharidin-induced skin blister assay to evaluate
the anti-inflammatory effects of drugs in healthy volunteers. The study
was designed as a randomized, double-blind, placebo-controlled, parallel
group trial. Twenty-five healthy male volunteers were randomized in a 1:1
ratio to receive AZI (500 mg once daily over 3 days) or placebo. Eligibility
criteria included age between 18 and 65 years, body weight above 50 kg,
and body mass index between 18.5 and 30 kg/m2. Subjects with a history
of HIV infection, hepatitis B or C, or sensitivity to AZI or macrolide/
ketolide antibiotics were excluded from the study. The clinical protocol
was approved by the Essex 2 Research Ethics Committee (09/H0302/50),
Cambridge, United Kingdom, and informed consent was obtained from
each subject prior to entering the study. This study was conducted in
accordance with good clinical practice (GCP) and all applicable regula-
tory requirements and the guiding principles of the Declaration of Hel-
sinki. The ClinicalTrials.gov identifier of this study is NCT01026064.
Drug administration and sample collection. Two capsules of 250 mg
AZI (Zithromax; Pfizer Ltd.) or matched placebo (Pharmaceutical Devel-
opment, GSK, Verona, Italy) were administered once daily for three con-
secutive days with 240 ml of water at 1 h before or 2 h after a meal. Blood
samples of 1 ml and 4 ml were collected before the last dose of study
medication and at 1, 2, 3, 4, 8, 24, 48, and 504 h (3 weeks) postdose for the
measurement of blood and plasma AZI concentrations, respectively.
Bioanalytical methods. AZI analysis was performed under the man-
agement of Worldwide Bioanalysis, DMPK, Verona, Italy, GlaxoSmith-
Kline. AZI concentrations were measured in hemolyzed blood (after 1:1
dilution with distilled water) and in plasma samples by high-performance
liquid chromatography/tandem mass spectrometry (LC-MS/MS) using a
validated analytical method. Samples were prepared by protein precipita-
tion. The lower limit of quantitation (LLOQ) of the assay was 2 ng/ml for
plasma and 4 ng/ml for blood. The within-run precision was 7.1% for both
the plasma and blood assays. The between-run precision was 9.5% and
3.5% for plasma and blood, respectively. The assay accuracy was between
14.4% and 10.2% for plasma and between 15% and 2.7% for blood.
Data analysis. The following noncompartmental pharmacokinetic
parameters were calculated for day 3 data using the Phoenix WinNonLin
(version 6.2) program (Pharsight Corporation): maximum plasma con-
centration (Cmax), the area under the curve during a 24-h dosing interval
(AUC24), and half-life. Compartmental population pharmacokinetic
models were developed using the first-order conditional estimation
method with interaction in the Phoenix NLME (version 1.1) program
(Pharsight Corporation). Model selection was based on the following cri-
teria: (i) successful minimization; (ii) visual inspection of goodness-of-fit
plots; (iii) a difference in objective function value (2 · log likelihood) of
more than 3.84, corresponding to a significance level (P value) of 0.05,
on the basis of the assumption of the objective functions for two nested
models differing by 1 degree of freedom; (iv) relative standard errors of
the parameter estimates; and (v) successful completion of the covariance
step. If the models being compared were not nested, the model selection
was based on goodness-of-fit plots and the Akaike information criterion.
Due to the narrow range of weights and the small number of subjects, no
subject characteristic could be included as a covariate in the model.
Pharmacokinetic model development. Model development was per-
formed in several steps. First, an exploratory analysis was undertaken to
investigate the basic structure of the plasma and blood concentration-
time profiles (alone and combined), including absorption (e.g., lag time,
transit compartments), distribution, and elimination components. Then
numerous integrated 3- and 4-compartment models in a catenary or mam-
millary structural arrangement were explored to simultaneously model the
plasma and whole-blood concentration-time data. A brief, nonexhaustive
synopsis of the numerous compartmental and semiphysiological models ex-
plored is presented in Fig. S1 in the supplemental material.
The final model chosen on the basis of goodness-of-fit criteria was a
3-compartment mammillary model with first-order absorption, lag time,
and first-order elimination from the central compartment (see model 3 in
Fig. S1 in the supplemental material), in which the relationship between
plasma and blood concentrations over time was described using an em-
pirical equation:
Cb  M · Cp  N · Cbc (1)
where Cb, Cbc, and Cp are the whole blood, blood cell, and total plasma
concentrations of AZI, respectively, and M and N are empirical, model-
estimated parameters (empirical coefficients to blood cell concentration
and plasma concentration, respectively). The differential equations of the
3-compartment model and the approach used to determine the appropri-
ate relationship between blood and plasma concentrations are presented
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in the section “Pharmacokinetic model development” in the supplemen-
tal material.
Pharmacostatistical model. An exponential variance model was used
to describe the interindividual variability:
Pi  Ppop · expi (2)
where Pi is the individual parameter estimate in the ith individual, Ppop is
an estimate of the population mean of parameter P, and i is the deviation
from the population mean for the ith individual under the assumption
that ’s are normally distributed with mean 0 and variance 2. Random
effects were initially modeled on clearance (CL) and the volume of the
central compartment. The requirement for additional random effects was
investigated by sequentially adding or removing them from the model.
When multiple random effects were included, both diagonal and full
block covariance matrices were explored.
For the residual variability, proportional error models were used for
both blood and plasma:
Yij  Cij · 1  ij (3)
where Yij is the observed blood or plasma concentration in the ith indi-
vidual at the jth time point, Cij is the predicted concentration, and εij is the
proportional residual error term under the assumption that ε  N(0, 2).
In addition, additive residual models were also explored but were rejected
on the basis of goodness-of-fit plots. Separate residual terms were used for
the blood and plasma measurements.
Model qualification. The final model was evaluated using the non-
parametric bootstrap and visual predictive check options in Phoenix
NLME (version 1.1). The precision of the parameter estimates was as-
sessed using a bootstrap analysis with 1,000 data sets, randomly sampled
from the original data set, with replacement. The final pharmacokinetic
model was fit to each of the data sets; the mean, standard error (SE), and
95% confidence intervals (CIs) of the model parameters were calculated
and compared with the final parameter estimates and SEs generated in
Phoenix NLME. A visual predictive check (VPC) was also performed to
evaluate the predictive properties of the model (n  1,000 data sets).
Treatment of plasma concentrations BLQ at 3 weeks. Because con-
centrations in plasma samples, but not blood samples, were below the
limit of quantification (BQL) at 3 weeks postdosing, initial analysis treated
these BQL values as missing, which led to a model in which there was no
difference in the accumulation of AZI in plasma or blood upon repeated
dosing (an unexpected finding). Further assumptions (e.g., setting the
BLQ concentrations to 0 or to one-half the LLOQ level) were not success-
ful. The method of treating the reported BLQ concentrations as true val-
ues weighted by the increased variability associated with the LLOQ con-
centrations was not examined because the requisite data were not
available. Furthermore, it was not possible to use the subject’s terminal
elimination half-life in plasma to estimate plasma concentrations at 3
weeks because the small duration of sample collection with quantifiable
concentrations was too short (e.g., 48 h, 2 times the half-life). Therefore,
the plasma BLQ concentrations at 3 weeks were extrapolated from the last
measurable plasma concentration using a literature-reported half-life of
78.6 h (51, 52), which allowed different levels of accumulation between
plasma and blood after long-term administration.
RESULTS
Subjects and exploratory analysis. The 12 male subjects who re-
ceived AZI had a median age of 29 years (range, 19 to 47 years), a
median height of 174.5 cm (range, 164 to 180 cm), and a median
weight of 73 kg (range, 61.1 to 87.9 kg). Noncompartmental anal-
ysis showed that AUC24 was more than 2-fold higher in blood than
plasma (Table 1). The mean (Fig. 1) as well as individual (data not
shown) blood AZI concentrations were greater than the mean
plasma concentrations over the entire sampling interval. These
profiles are indicative of an extensive uptake of the drug from
plasma into the blood cell compartment, consistent with previous
reports of AZI accumulation in white blood cells.
Population pharmacokinetic analysis. The disposition of AZI
in whole blood and plasma was adequately described by a 3-com-
partment model. The model was parameterized with a first-order
absorption rate constant (ka); absorption lag time (Tlag); apparent
volume of distribution of the central compartment, assumed to be
plasma (Vp/F); apparent volume of distribution of one peripheral
compartment, assumed to be the blood cells (Vbc/F); apparent
volume of distribution of the second peripheral compartment,
assumed to be the fibroblasts in tissues (Vt/F); two apparent dis-
tributional clearances between the central (blood cell) and periph-
eral (tissue) compartments (CLbc/F and CLt/F, respectively); and
an apparent elimination clearance (CL/F).
Assuming that the central compartment represents plasma and
that one of the peripheral compartments represents the blood
cells, the concentration in blood can be expressed as a function of
the concentration in plasma, the concentration in blood cells, and
the hematocrit (see “Pharmacokinetic model development” and
equation 8 in the supplemental material). However, this relation-
ship did not result in an acceptable model fit. This was probably
TABLE 1 Pharmacokinetic parameters determined by noncompartmental analysisa
Matrix Cmax (g/liter) Tmax (h)
AUC24 (g · h/liter)
on day 3 t1/2 (h) Vz/F (liters) CL/F (liter/h)
Blood 772 (39.0) 3.00 (1.95–4.00) 7,893 (30.4) 117 (33.1) 10,700 (33.6) 63.3 (30.4)
Plasma 500 (44.4) 2.02 (1.95–3.95) 3,468 (27.5) 27.2 (20.6)b 5,670 (33.1) 144 (27.5)
a Data represent geometric mean values (geometric coefficient of variation [in percent]) for all parameters except the time to the maximum concentration in plasma, which is
presented as the median (range). Cmax, maximum concentration in plasma; Tmax, time to maximum concentration in plasma; AUC24, area under the curve during a 24-h dosing
interval; t1/2, half-life; Vz/F, volume of distribution based on the terminal phase; CL/F, clearance.
b Plasma concentrations were quantifiable up to 48 h in all subjects. Therefore, due to the limited number of data points available, the half-life in plasma should be interpreted with
caution.
FIG 1 AZI blood () and plasma (Œ) concentration-time profiles. Data rep-
resent the mean concentration-time profiles in blood and plasma for up to 48
h following the last of the three (500-mg) doses of AZI given once daily.
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due in part to insufficient data to accurately describe the intracel-
lular sequestration of AZI in lysosomes, the kinetics of release
from the cellular compartment, as well as the nonlinear kinetics of
AZI binding to plasma proteins. In addition, the hematocrit value
is driven by red blood cells, which do not accumulate AZI. To
compensate for this lack of information, a modified, empirical
equation was used to describe the mathematical relationship be-
tween the concentrations in plasma and whole blood (equation 1).
The blood concentration in one subject and all the plasma
concentrations at the 504-h time point (3 weeks) were below the
LLOQ (BLQ). Ignoring the BLQ values at 504 h postdose resulted
in a model which suggested that plasma concentrations remained
elevated over 3 weeks; this was inconsistent with the observed
data. Therefore, the missing plasma concentrations in each indi-
vidual were calculated assuming exponential decay in the terminal
elimination phase and using the last measurable plasma concen-
tration and a previously published half-life of 78.6 h (51, 52) (see
“Treatment of plasma concentrations BLQ at 3 weeks” in Materi-
als and Methods).
The final model structure is shown in Fig. 2. Goodness-of-fit
plots for observed versus population predicted, observed versus
individual predicted, and conditional weighted residuals
(CWRES) versus population predicted concentrations are pre-
sented in Fig. 3. The observed versus population predicted plots
show a uniform distribution of the data points across the line of
unity. The observed versus individual predicted concentration
plots suggest a relatively small underprediction of the higher
(peak) concentrations in both plasma and blood. CWRES versus
population predicted concentrations showed little to no bias. In-
dividual predictions of blood concentration-time and plasma
concentration-time data after the last dose are shown in Fig. S2
and S3 in the supplemental material, respectively. Consistent with
the observed versus individual predicted concentration plots,
these graphs also show a slight underprediction of the peak con-
centrations in both the plasma and blood of some subjects.
Following a mean lag time of 0.95 h, absorption was rapid
(ka  0.604 h
1). The two peripheral compartments exhibited
very large volumes of distribution, both of which were signifi-
cantly larger than the volume of distribution in the central com-
partment, consistent with the known extensive distribution of AZI
in peripheral tissues and cells. Thus, Vbc/F was 3,084 liters and
Vt/F was 2,980 liters, while Vp/F was 440 liters. The distributional
clearance into the blood cell compartment was significantly
smaller than the distributional clearance into the second periph-
eral compartment (17.8 versus 213 liters/h). The uncertainty, ex-
pressed as the percent relative standard error (RSE) for the fixed-
effects parameters, was low to moderate, ranging from 6.8 to
43.7%. The magnitude of the interindividual variability (percent
coefficient of variation [CV]) was low in CLt/F (8.2%), moderate
in the elimination CL/F and absorption rate constant (30.3% and
26.2%, respectively), and high in Vp/F (107.3%). Interindividual
variability could not be estimated for the intercompartmental dis-
tributional clearances or for Vbc/F. Proportional residual error
(percent CV) was estimated to be 24.1% in plasma and 23.2% in
blood. Shrinkage was calculated for interindividual and residual
variability parameters, and it was below 20% in all cases (53).
Model qualification. The diagnostic plots (Fig. 3) indicated
that the model adequately described the data. The results of the
bootstraps, expressed as the median (95% CI) parameter esti-
mates, are presented in Table 2. The median from the parameter
bootstrap was within 10% for the typical values of CL/F, Vbc/F,
CLbc/F, Vt/F, Tlag, M, and N and within 26% for the typical values
of Vp/F and CLt/F. For ka, the median from the parameter boot-
strap was within 44% of the typical value. Visual predictive check
plots for plasma and whole blood show that most of the concen-
trations observed in both plasma and blood were within the pre-
dicted 5% and 95% quantiles (Fig. 4).
Simulation of plasma and blood concentrations after long-
term administration. The final model was used to predict the
FIG 2 Diagram of the 3-compartment structural model for AZI concentra-
tions in blood and plasma. ka, absorption rate constant; Tlag, lag time; Cp,
plasma concentration; Ct, concentration in peripheral compartment, assumed
to be tissue; Cbc, concentration in peripheral compartment, assumed to be
blood cells; CLt, intercompartmental clearance to tissue compartment; CLbc,
intercompartmental clearance to blood cell compartment; CL, elimination
clearance; M, empirical coefficient to blood cell concentration; N, empirical
coefficient to plasma concentration.
FIG 3 Goodness-of-fit graphics for blood (left) and plasma (right). Graphs
depict the observed concentrations versus the population predictions (A), the
observed concentrations versus the individual predictions (B), and the
CWRES versus the population predictions (C). The line of identity is included
in panels A and B.
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concentration-time profiles of AZI in plasma and blood after pro-
longed administration of 500 mg AZI once daily for 30 days. The
simulation results are displayed in Fig. 5 and show that AZI
reaches steady-state concentrations in plasma at 5 days, while AZI
continues to accumulate in whole blood even after 30 days of
administration. Furthermore, these simulations predict a mean
blood/plasma accumulation ratio of 4-fold following long-term
once-daily administration of 500 mg AZI. This ratio is in line with
the 5-fold accumulation ratio calculated on the basis of blood and
plasma concentration data from cystic fibrosis patients following
long-term daily administration of 500 mg AZI (49).
DISCUSSION
Given the pharmacodynamics and unique plasma and blood cell
pharmacokinetics of AZI, the majority of studies to date have
focused on AZI accumulation in PMNs or PBMCs and on plasma
distribution. Freeman et al. (44) demonstrated that AZI accumu-
lates in PMNs and that PMNs serve as a unique system for delivery
of the drug to the site of infection. Olsen et al. (54) demonstrated
that AZI accumulates extensively in PBMCs. Ballow and Amsden
provided additional evidence for AZI accumulation in PMNs and
studied the pharmacokinetics of the AZI distribution between
plasma and PMNs using a compartmental modeling approach
TABLE 2 Parameter estimates by bootstrap analysis





Absorption rate constant ka (h
1) 1.06 0.485 5.820
Lag time Tlag (h) 1.25 0.93 1.94
Plasma vol of distribution Vp/F (liters) 452 40 1,036
Blood cell vol of distribution Vbc/F (liters) 3,001 2,360 3,871
Tissue compartment vol of distribution Vt/F (liters) 2,785 2,227 3,593
Elimination clearance CL/F (liters/h) 115 100 134
Intercompartmental clearance to blood cell compartment CLbc/F (liters/h) 16.1 11.5 25.2
Intercompartmental clearance to tissue compartment CLt/F (liters/h) 289 167 554
Blood cell concn coefficient in equation 1 M 1.64 1.53 1.74















a Bootstraps with 1,000 data sets were performed.
b IIV, interindividual variability.
FIG 4 Visual predictive check (VPC) in blood (A) and plasma (B). Open
circles, observed data points; solid line, predicted 50th percentile; shaded area,
area between the predicted 5th and 95th quantiles. Ideally, 90% of the obser-
vations should fall inside the 90% prediction interval.
FIG 5 Predictions of AZI accumulation in blood and plasma after long-term
(30 days) administration of 500 mg daily. Bold, dashed lines, predicted blood
concentration-time profile; thin, solid lines, predicted plasma concentration-
time profile.
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(38). Due to the demonstrated importance of AZI accumulation
in both PMNs and PBMCs, as well as the fact that AZI may dis-
tribute transiently into erythrocytes (55), we aimed to develop an
all-inclusive pharmacokinetic model that described the relation-
ship between plasma and whole-blood AZI concentrations fol-
lowing the last dose of a 500-mg-once-daily regimen for 3 consec-
utive days.
A nonlinear mixed-effects population modeling approach was
employed. A three-compartment model with first-order absorp-
tion, lag time, and first-order elimination best described the blood
and plasma disposition of AZI after oral administration of three
500-mg daily doses. Blood concentrations were described using an
empirical approach based on the assumption that plasma concen-
trations were sampled from the central compartment and that one
of the peripheral compartments represented the blood cells.
Previously, Ballow and Amsden studied the compartmental
distribution of AZI based on the comodeling of plasma and urine
data (51). The final model included two peripheral compartments
differing in rates of equilibration: one fast and one slow (CLdf/F 
61.3 liters/h and CLds/F  253 liters/h, respectively), where CLdf/F
and CLds/F are the distributional clearances of the fast and slow
equilibrating peripheral compartments, respectively. In addition,
the two peripheral compartments had very large volumes of dis-
tribution of 4,304 liters and 3,707 liters, respectively, and a re-
ported elimination CL of 153 liters/h. The population pharmaco-
kinetic model presented here resulted in similar (although not
identical) fixed parameter values.
A number of limitations of this model could be identified.
First, the model-estimated interindividual variability in Vp/F was
high (107.3%). This might be explained, in part, by the absence of
data to properly describe the nonlinear binding of AZI to plasma
proteins observed over the range of therapeutic concentrations
(41). Second, bootstrap analysis showed a high degree of uncer-
tainty in the ka parameter estimate. Third, plots of the predicted
versus measured concentrations showed that the peak concentra-
tions were underpredicted in both plasma and blood. This under-
prediction was not improved by adding transit compartments,
deleting the lag time, or changing intersubject variability on these
parameters. Fourth, using the literature-published plasma half-
life of 78.6 h to extrapolate the plasma concentration at 3 weeks
limits the description of interindividual variability in CL and V.
Lastly, after exploring over 350 models in total, an empirically
derived equation was employed to describe the relationship be-
tween blood and plasma concentrations (equation 1). The fact
that we were not able to use a physiological relationship may be
due to the lack of information regarding the nonlinear binding of
AZI to plasma proteins and to the kinetics of intracellular drug
uptake and sequestration in lysosomes. Even with these limita-
tions, the model was well described and able to predict concentra-
tions after daily dosing of AZI in CF patients.
A phase III study (22) showed that AZI, although investiga-
tional, is effective in subjects with CF who are chronically infected
with Pseudomonas aeruginosa. In addition, long-term therapy
with 250-mg daily doses of AZI for 1 year was shown to decrease
the frequency of exacerbations in COPD patients (14), and long-
term treatment with 250 mg thrice weekly was effective in preven-
tion and treatment of BOS in lung transplant patients (25). The
promising clinical data on AZI efficacy in patients with bronchi-
ectasis or severe persistent asthma need to be confirmed in ran-
domized, placebo-controlled studies (16, 27, 33, 34).
While diverse dosing regimens of AZI were tested in patients
with chronic inflammation of the lower airways, limited data
about the systemic exposure achieved in these patients exist.
Wilms et al. reported that after at least 35 days of once-daily treat-
ment with 500 mg AZI in CF patients, the Cmax in plasma was 0.67
g/ml and the AUC24 was 5.3 g · h/ml (49). The corresponding
values in blood were 2.01 g/ml and 27.8 g · h/ml; i.e., they were
3- and 5-fold higher than those in plasma, respectively. Elimina-
tion half-lives were 102 h in plasma and 178 h in blood (49). A
subsequent study in CF patients treated with 1,000 mg AZI once
weekly for 3 months revealed that AUC168 was 3.5 times higher in
blood than in plasma (12). Thus, the ability to predict the accu-
mulation of AZI in patients after long-term administration is clin-
ically relevant.
To determine AZI concentration-time profiles after long-term
administration, the plasma and blood concentrations were simu-
lated using a conservative, deterministic simulation based on the
current data set, for which the individual interindividual variabil-
ity was determined. The simulation results presented here showed
a 4-fold accumulation in blood compared to that in plasma, con-
sistent with the observations in CF patients. This suggests that
both plasma and blood concentrations of AZI should be consid-
ered in establishing a pharmacokinetic/pharmacodynamic rela-
tionship in nonclinical and clinical studies. Considering that AZI
accumulates in white blood cells and modulates their function, it
is likely that whole-blood concentrations are more predictive of
efficacy than plasma concentrations (49). Furthermore, in spite of
the limitations discussed above, the fact that the blood/plasma
accumulation predicted by the simulation presented is in line with
the blood/plasma accumulation observed in CF patients provides
an external validation of our model and suggests that the model is
acceptable for future use in predicting the blood exposures follow-
ing long-term administration of AZI in different chronic inflam-
matory diseases.
In conclusion, the presented population pharmacokinetic
model describing AZI concentrations in plasma and blood after
repeated oral dosing can be utilized to predict the plasma and
blood concentrations under various AZI dosing regimens. These
data may be used to outline the clinically effective exposure in
investigational studies in patients with CF, COPD, or BOS and
select the most promising treatment schedules for patients with
other chronic inflammatory lung diseases. Also, the model may be
used as a starting point for prediction of long-term exposure in
humans of novel compounds which exhibit an AZI-like pharma-
cokinetic disposition.
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